Genmab - ADR
GMAB
Market Cap$12.9B
Close$
$7.99
63.3% downside
Current Fair Value
63.3% downsideOvervalued by 63.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.90 Billion |
|---|---|
| Enterprise Value | $11.66 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $12.14 |
| Beta | 0.9 |
| Outstanding Shares | 637,254,900 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 13.09 |
|---|---|
| PEG | -15.35 |
| Price to Sales | 0.78 |
| Price to Book Ratio | 2.72 |
| Enterprise Value to Revenue | 0.64 |
| Enterprise Value to EBIT | 1.93 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Genmab
CEO: Jan van de Winkel